Comparison 22.
Infections ‐ absolute risk difference (ARD)
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 All studies | 15 | 793 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.08 [‐0.13, ‐0.02] |
| 2 Trials with total numbers (Meng) excluded | 14 | 749 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.08 [‐0.14, ‐0.03] |
| 3 Parenteral nutrition | 2 | 164 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.10 [‐0.22, 0.03] |
| 3.1 Medical trials | 1 | 40 | Risk Difference (M‐H, Fixed, 95% CI) | 0.2 [0.01, 0.39] |
| 3.2 Surgical trials | 1 | 124 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.19 [‐0.35, ‐0.04] |
| 4 Enteral nutrition | 6 | 267 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.08 [‐0.19, 0.03] |
| 4.1 Medical trials | 4 | 176 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.03 [‐0.16, 0.11] |
| 4.2 Surgical trials | 2 | 91 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.18 [‐0.35, ‐0.01] |
| 5 Supplements | 7 | 362 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.07 [‐0.14, 0.00] |
| 5.1 Medical trials | 4 | 268 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.08 [‐0.15, ‐0.00] |
| 5.2 Surgical trials | 3 | 94 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.04 [‐0.21, 0.13] |
| 6 Medical trials | 9 | 484 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.04 [‐0.10, 0.03] |
| 7 Surgical trials | 6 | 309 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.14 [‐0.24, ‐0.05] |
| 8 Alcoholic hepatitis | 2 | 115 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.14 [‐0.30, 0.02] |
| 9 Cirrhosis | 7 | 336 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.04 [‐0.13, 0.04] |
| 9.1 Parenteral nutrition | 1 | 40 | Risk Difference (M‐H, Fixed, 95% CI) | 0.2 [0.01, 0.39] |
| 9.2 Enteral nutrition | 3 | 112 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.04 [‐0.20, 0.13] |
| 9.3 Supplements | 3 | 184 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.10 [‐0.21, 0.00] |
| 10 HCC | 2 | 208 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.13 [‐0.22, ‐0.03] |
| 10.1 Parenteral nutrition | 1 | 124 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.19 [‐0.35, ‐0.04] |
| 10.2 Enteral nutrition | 0 | 0 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 10.3 Supplements | 1 | 84 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.02 [‐0.09, 0.04] |
| 11 Abstracts excluded | 14 | 738 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.07 [‐0.13, ‐0.02] |
| 12 Abstracts excluded | 14 | 738 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.07 [‐0.13, ‐0.02] |
| 12.1 Parenteral nutrition | 2 | 164 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.10 [‐0.22, 0.03] |
| 12.2 Enteral nutrition | 5 | 212 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.06 [‐0.18, 0.05] |
| 12.3 Supplements | 7 | 362 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.07 [‐0.14, 0.00] |
| 13 Surgical trials excluding transplants | 5 | 278 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.13 [‐0.23, ‐0.03] |
| 14 Parenteral nutrition ‐ best‐case scenario | 2 | 190 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.23 [‐0.35, ‐0.11] |
| 14.1 Medical trials | 1 | 40 | Risk Difference (M‐H, Fixed, 95% CI) | 0.2 [0.01, 0.39] |
| 14.2 Surgical trials | 1 | 150 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.35 [‐0.49, ‐0.21] |
| 15 Parenteral nutrition ‐ worst‐case scenario | 2 | 190 | Risk Difference (M‐H, Fixed, 95% CI) | 0.04 [‐0.08, 0.16] |
| 15.1 Medical trials | 1 | 40 | Risk Difference (M‐H, Fixed, 95% CI) | 0.2 [0.01, 0.39] |
| 15.2 Surgical trials | 1 | 150 | Risk Difference (M‐H, Fixed, 95% CI) | 0.0 [‐0.15, 0.15] |
| 16 Enteral nutrition ‐ best‐case scenario | 6 | 298 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.17 [‐0.27, ‐0.07] |
| 16.1 Medical trials | 4 | 184 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.08 [‐0.21, 0.06] |
| 16.2 Surgical trials | 2 | 114 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.32 [‐0.46, ‐0.17] |
| 17 Enteral nutrition ‐ worst‐case scenario | 6 | 298 | Risk Difference (M‐H, Fixed, 95% CI) | 0.04 [‐0.06, 0.15] |
| 17.1 Medical trials | 4 | 184 | Risk Difference (M‐H, Fixed, 95% CI) | 0.01 [‐0.12, 0.15] |
| 17.2 Surgical trials | 2 | 114 | Risk Difference (M‐H, Fixed, 95% CI) | 0.09 [‐0.08, 0.26] |
| 18 Supplements ‐ best‐case scenario | 7 | 401 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.16 [‐0.23, ‐0.10] |
| 18.1 Medical trials | 4 | 286 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.13 [‐0.21, ‐0.06] |
| 18.2 Surgical trials | 3 | 115 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.24 [‐0.40, ‐0.09] |
| 19 Supplements ‐ worst‐case scenario | 7 | 401 | Risk Difference (M‐H, Fixed, 95% CI) | 0.02 [‐0.05, 0.10] |
| 19.1 Medical trials | 4 | 286 | Risk Difference (M‐H, Fixed, 95% CI) | ‐0.00 [‐0.08, 0.07] |
| 19.2 Surgical trials | 3 | 115 | Risk Difference (M‐H, Fixed, 95% CI) | 0.09 [‐0.06, 0.25] |